# Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)

Source: https://onco.cc/trials/nct07219459/  
OnCo record `nct07219459` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Visugromab, Nivolumab, Lenvatinib in hepatocellular carcinoma, run by CatalYm GmbH, now recruiting.

## Summary

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure is a phase 2 interventional study registered as NCT07219459 by CatalYm GmbH, with 104 participants planned, started 2026-03-19 and due to reach its primary completion in 2029-09. Interventions recorded: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion. Conditions listed: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07219459
- Phase: 2
- Setting: A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)
- Sponsor: CatalYm GmbH
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT07219459: https://clinicaltrials.gov/study/NCT07219459

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Visugromab](https://onco.cc/drugs/visugromab/)
- companies: [CatalYm](https://onco.cc/companies/catalym/)

---
JSON: https://onco.cc/api/v1/entities/nct07219459.json